MedTrace Logo

Study to Evaluate Potential Food Effects

NCT00791817 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-09-07

Study results available
· View outcomes & findings →

Summary

Half the group will be given a high fat diet and the other half will fast. They will then be crossed over.

Conditions

  • Healthy

Interventions

DRUG

PG-760564

200 mg capsule, single dose,fasted when dosed, duration is 4 days

DRUG

PG-760564

200 mg capsule, single dose,high fat diet when dosed, duration is 4 days

Sponsors & Collaborators

  • Procter and Gamble

    lead INDUSTRY

Principal Investigators

  • William S Aronstein, MD, PhD · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791817 on ClinicalTrials.gov